Home/Filings/4/0001062993-24-000924
4//SEC Filing

Menold Daniel 4

Accession 0001062993-24-000924

CIK 0001042074other

Filed

Jan 15, 7:00 PM ET

Accepted

Jan 16, 7:07 PM ET

Size

9.0 KB

Accession

0001062993-24-000924

Insider Transaction Report

Form 4
Period: 2024-01-16
Menold Daniel
Vice President, Finance
Transactions
  • Exercise/Conversion

    Common Stock

    2024-01-16$4.05/sh+10,000$40,50010,000 total
  • Sale

    Common Stock

    2024-01-16$23.58/sh10,000$235,8060 total
  • Exercise/Conversion

    Employee Stock Option (right to buy)

    2024-01-1610,000135,109 total
    Exercise: $4.05Exp: 2030-05-14Common Stock (10,000 underlying)
Footnotes (3)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on April 10, 2023.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.47 to $23.74, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The shares subject to the option vest in 48 equal monthly installments commencing on January 31, 2020.

Issuer

CymaBay Therapeutics, Inc.

CIK 0001042074

Entity typeother

Related Parties

1
  • filerCIK 0001705745

Filing Metadata

Form type
4
Filed
Jan 15, 7:00 PM ET
Accepted
Jan 16, 7:07 PM ET
Size
9.0 KB